News
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports First Quarter 2026 Financials
Jaguar Health, Inc. reports significant revenue increase driven by license agreements for Mytesi® and Canalevia®-CA1, focuses on crofelemer development for rare intestinal indications. Upcoming presentations at ESPGHAN Meeting. Info on investor webcast and CEO's virtual presentation -
COMMUNIQUÉ DE PRESSE
Fox River Resources Corporation Obtains Interim Order for Plan of Arrangement and Provides Details of Special Meeting
Fox River Resources Corp. obtains interim court order for proposed arrangement with Avenir Minerals Ltd. Shareholders urged to vote on Arrangement Resolution by June 19 -
-
-
-
COMMUNIQUÉ DE PRESSE
Informations privilégiées / Autres communiqués
MaaT Pharma fait le point sur la demande d'autorisation de mise sur le marché de MaaT013 (Xervyteg) pour le traitement de la maladie aiguë du greffon contre l'hôte, suite à une tendance négative lors de l'audition orale devant le CHMP de l'EMA -
-
-